The biopharma sector's research and development investments are continuing to increase. An in-depth analysis by BioWorld Insight of the second-quarter 2018 financial reports from the top 100 public biopharmaceutical companies by market cap, excluding big pharma companies, found that collectively they invested over 22 percent more in R&D during the first two quarters of 2018 than they did in the comparable period last year. A whopping $19.2 billion has so far been spent compared to $15.7 billion last year.